171 related articles for article (PubMed ID: 27501852)
1. Repositioning organohalogen drugs: a case study for identification of potent B-Raf V600E inhibitors via docking and bioassay.
Li Y; Guo B; Xu Z; Li B; Cai T; Zhang X; Yu Y; Wang H; Shi J; Zhu W
Sci Rep; 2016 Aug; 6():31074. PubMed ID: 27501852
[TBL] [Abstract][Full Text] [Related]
2. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
3. Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors.
Xu Z; Yan G; Wang G; Li B; Zhu J; Sun P; Zhang X; Luo C; Wang H; Zhu W
Bioorg Med Chem Lett; 2012 Sep; 22(17):5428-37. PubMed ID: 22858139
[TBL] [Abstract][Full Text] [Related]
4. Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.
Bandaru S; Sumithnath TG; Sharda S; Lakhotia S; Sharma A; Jain A; Hussain T; Nayarisseri A; Singh SK
Curr Drug Metab; 2017 Jul; 18(6):527-534. PubMed ID: 28472910
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.
Kadioglu O; Saeed MEM; Greten HJ; Mayr K; Schrama D; Roos WP; Efferth T
J Am Acad Dermatol; 2021 Apr; 84(4):1086-1089. PubMed ID: 32707252
[No Abstract] [Full Text] [Related]
6. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
[TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.
Duffey MO; Adams R; Blackburn C; Chau RW; Chen S; Galvin KM; Garcia K; Gould AE; Greenspan PD; Harrison S; Huang SC; Kim MS; Kulkarni B; Langston S; Liu JX; Ma LT; Menon S; Nagayoshi M; Rowland RS; Vos TJ; Xu T; Yang JJ; Yu S; Zhang Q
Bioorg Med Chem Lett; 2010 Aug; 20(16):4800-4. PubMed ID: 20634068
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting
Abdel-Maksoud MS; Ali EMH; Ammar UM; Mersal KI; Yoo KH; Oh CH
Bioorg Med Chem; 2020 Jun; 28(11):115493. PubMed ID: 32340792
[TBL] [Abstract][Full Text] [Related]
9. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization.
Kong X; Qin J; Li Z; Vultur A; Tong L; Feng E; Rajan G; Liu S; Lu J; Liang Z; Zheng M; Zhu W; Jiang H; Herlyn M; Liu H; Marmorstein R; Luo C
Org Biomol Chem; 2012 Sep; 10(36):7402-17. PubMed ID: 22875039
[TBL] [Abstract][Full Text] [Related]
11. Identification and Biological Evaluation of Novel Type II B-Raf
Wang PF; Wang ZF; Qiu HY; Huang Y; Hu HM; Wang ZC; Zhu HL
ChemMedChem; 2018 Dec; 13(23):2558-2566. PubMed ID: 30353975
[TBL] [Abstract][Full Text] [Related]
12. Design of potent B-Raf
Wang ZF; Wang PF; Ma JT; Chai YZ; Hu HM; Gao WL; Wang ZC; Wang BZ; Zhu HL
Chem Biol Drug Des; 2018 Feb; 91(2):567-574. PubMed ID: 29045039
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
[TBL] [Abstract][Full Text] [Related]
14. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.
Li X; Shen J; Tan L; Zhang Z; Gao D; Luo J; Cheng H; Zhou X; Ma J; Ding K; Lu X
Bioorg Med Chem Lett; 2016 Jun; 26(12):2760-2763. PubMed ID: 27155899
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
Blackburn C; Duffey MO; Gould AE; Kulkarni B; Liu JX; Menon S; Nagayoshi M; Vos TJ; Williams J
Bioorg Med Chem Lett; 2010 Aug; 20(16):4795-9. PubMed ID: 20630752
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
18. Novel natural inhibitors targeting B-RAF(V600E) by computational study.
Wu B; Zhang Z; Dou G; Lv X; Ge J; Wang H; Xie H; Zhu D
Bioengineered; 2021 Dec; 12(1):2970-2983. PubMed ID: 34252351
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
[TBL] [Abstract][Full Text] [Related]
20. 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF
El-Damasy AK; Haque MM; Park JW; Shin SC; Lee JS; EunKyeong Kim E; Keum G
Eur J Med Chem; 2020 Dec; 208():112756. PubMed ID: 32942186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]